Harpoon Therapeutics, Inc. (HARP)
Market Cap | 27.87M |
Revenue (ttm) | 31.92M |
Net Income (ttm) | -67.73M |
Shares Out | 37.45M |
EPS (ttm) | -2.04 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 197,513 |
Open | 0.685 |
Previous Close | 0.691 |
Day's Range | 0.685 - 0.750 |
52-Week Range | 0.586 - 5.160 |
Beta | 1.56 |
Analysts | Buy |
Price Target | 6.95 (+833.89%) |
Earnings Date | May 11, 2023 |
About HARP
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II cl... [Read more]
Financial Performance
In 2022, HARP's revenue was $31.92 million, an increase of 34.92% compared to the previous year's $23.65 million. Losses were -$67.73 million, -41.97% less than in 2021.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for HARP stock is "Buy." The 12-month stock price forecast is $6.95, which is an increase of 833.89% from the latest price.
News

Harpoon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
HPN217 (BCMA) and HPN328 (DLL3) enrollment on track, with data updates and selection of recommended Phase 2 doses for both active clinical programs planned in 2023

Harpoon Therapeutics Announces Closing of $25 Million Private Placement
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers, to...

Harpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced th...

Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced tha...

The 3 Most Undervalued Penny Stocks to Buy in February 2023
If finding undervalued stocks is good, then finding undervalued penny stocks is even better. That's because, with penny stocks, investors' capital appreciation upside potential is amplified.

New Strong Buy Stocks for January 27th
GWRS, EVBG, SPLK, RELL and HARP have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2023.

Why Fast-paced Mover Harpoon Therapeutics, Inc. (HARP) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harpoon Therapeutics, Inc. (HARP) could be a great choice. It is one of the several ...

7 Stocks to Add to Your 10x Watchlist
There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfol...

Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%.

Three Small-Cap Biotech Stocks to Consider Now
This article looks at three small-cap biotech companies with stock prices that are making significant moves and have a bright outlook for 2023

Why Is Harpoon Therapeutics (HARP) Stock Up 100%+ Today?
Harpoon Therapeutics (NASDAQ: HARP) stock is taking off on Monday following the release of updated results from its myeloma drug candidate. HPN217 is the company's drug candidate currently undergoing...

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today presented upd...

Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ...

Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ...

Harpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Tops Revenue Estimates
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 41.67% and 73.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

Harpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial Results
HPN217 (BCMA) interim data update at ASH 2022; HPN328 (DLL3) exploring dosing regimens and HPN601 (EpCAM) expected to enter the clinic in 2023

Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
Updated interim results from Phase 1 clinical trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma to be presented in a poster at ASH on Sunday, December 11, 2022, ...

Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
Harpoon adds experienced drug developer to leadership team Harpoon adds experienced drug developer to leadership team

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors
Industry veteran Lauren Silvernail brings over 30 years of experience in financial leadership roles at life science and related companies Industry veteran Lauren Silvernail brings over 30 years of exp...

Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that...

Harpoon Therapeutics, Inc. (HARP) Reports Q2 Loss, Misses Revenue Estimates
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 3.64% and 9.95%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock...

Harpoon Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting

Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that ...

Harpoon Therapeutics Expands Leadership Team
SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the a...

Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced interi...